Application status and thinking of minimal residual disease-monitoring in multiple my-eloma after stem cell transplantation / 中国肿瘤临床

ABSTRACT

The efficacy of multiple myeloma (MM) treatments, particularly novel medicines and transplantation, has improved rapidly in the last ten years, with increasing rates of progression-free survival (PFS) and overall survival (OS). However, complete response (CR) is not enough as prognostic indicator guidance. Therefore, methods have been developed to monitor minimal residual disease (MRD), such as serum free light chain (sFLC), flow cytometry, polymerase chain reaction (PCR), next generation sequencing (NGS), and PET-CT. This article reviewed the current situation of the application of those methods in MM patients after stem cell transplantation.